

# NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer's Disease Treatment

*Progress in Neurodegenerative Research:  
NKGen's Phase 1/2a Clinical Trial for  
SKN01 on Track for End-of-Year Initiation.*

SANTA ANA, CA, USA, October 24, 2023 /EINPresswire.com/ -- Today, [NKGen](#) Biotech Inc. ([Nasdaq: NKGN](#)), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its [SKN01](#) program targeting Alzheimer's Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial by the close of 2023, focusing on patients with moderate Alzheimer's Disease.



SKN01 is a unique, non-genetically modified NK cell therapy that exhibits heightened cytotoxic capabilities and receptor activation, standing out as a promising therapeutic option. The forthcoming clinical trial is set to enroll 30 participants, aiming to unravel the potential benefits of this innovative treatment, with preliminary data expected to roll out in early Q3 2024.

Encouraging trends have emerged from the SKN01 program, as showcased in poster presentations at the Alzheimer's Association International Conference (AAIC) in July and the World Congress of Neurology (WCN) in October 2023. The data revealed that SKN01 was not only well-tolerated but also effectively crossed the blood-brain barrier. This was associated with a dose-dependent decrease in proteins linked to neuroinflammation, all without triggering serious adverse effects.

Situated in Santa Ana, California, NKGen Biotech is a pioneering force in the development of innovative natural killer cell therapeutics, including autologous, allogeneic, and CAR-NK options. Learn more about our groundbreaking work at [www.nkgenbiotech.com](http://www.nkgenbiotech.com).

#### Forward-Looking Statements Disclaimer

This press release contains projections and other forward-looking statements regarding future events. These statements are predictions and are subject to risks and uncertainties that could cause actual outcomes to differ materially. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on the information available to the Company as of the date of this release and are subject to several risks, uncertainties, and other factors that could cause the Company's actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.

#### Contact Information

[dz@amplifiPR.com](mailto:dz@amplifiPR.com)

Amplifi Powered by Plato

Bryan Feinberg

Amplifi / Plato

+1 551-574-2169

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/663835807>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.